News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

H. Lundbeck A/S (LUN.CO) Release: New Study Results Demonstrate Brintellix® (Vortioxetine) Is Efficacious In Asian Patients Suffering From Depression


6/26/2014 7:37:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Valby, 2014-06-26 06:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) announced results of the SOLUTION trial conducted in Asian patients suffering from Major Depressive Disorder (MDD), more commonly referred to as depression. In this head-to-head study, Brintellix® (vortioxetine) was at least as efficacious as venlafaxine on the primary efficacy endpoint was better tolerated than venlafaxine. The data, one of the 15 Brintellix abstracts accepted for presentation at the Congress of the International College of Neuropsychopharmacology (CINP) have been presented for the first time during a poster session (P-42-33 Depression C) on the 25th of June at 5:15pm PDT.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES